Harvard Apparatus Regenerative Technology, Inc. reports developments as a clinical-stage biotechnology company focused on technology intended to regenerate organs inside the body. Company updates center on its cell-based scaffold platform and the Cellspan Esophageal Implant program for severe esophageal disease, including esophageal atresia and repair of esophageal damage caused by cancer or injury.
Recurring news also covers research collaborations applying the platform to colon repair after colectomy and uterine tissue repair, orphan-drug designations in the U.S. and Europe, patent portfolio updates, clinical-program activity, private placements, convertible debt, financial results, and board composition.
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
FAQ
What is the current stock price of Harvard Apprats REG TCH (HRGN)?
Harvard Apprats REG TCH (HRGN) last closed at $2.30.
What is the market cap of Harvard Apprats REG TCH (HRGN)?
The market cap of Harvard Apprats REG TCH (HRGN) is approximately $46.7M.